

ANNEX A

Unconditional amendments to EP (UK) 2 322 153 (“EP 153”):

1. A compound that inhibits hypoxia inducible factor (HIF) prolyl hydroxylase activity for use in treating or preventing iron deficiency in a subject, wherein the compound is a structural mimetic of 2-oxoglutarate.

Claims 2 and 10 are deleted and Claims 3-11 are renumbered accordingly, i.e. as follows:

~~2. A compound that inhibits hypoxia inducible factor (HIF) hydroxylase activity for use in treating or preventing microcytosis associated with iron deficiency in a subject, wherein the compound is a structural mimetic of 2-oxoglutarate.~~

~~3~~2. The compound of claim 1 for the use of that claim, wherein the iron deficiency is functional iron deficiency.

~~4~~3. The compound of claim 1 for the use of that claim, wherein the iron deficiency is associated with a disorder selected from the group consisting of anemia, iron deficiency anemia, microcytic anemia, inflammation, infection, immunodeficiency disorder and neoplastic disorder.

~~5~~4. The compound of claim 1 for the use of that claim, wherein the compound is for use in increasing iron absorption.

~~6~~5. The compound of claim ~~5~~4 for the use of that claim, wherein the iron absorption is in the intestine, is in duodenal enterocytes, or is absorption of dietary iron.

~~7~~6. The compound of claim 1 for the use of that claim, wherein the compound is for use in increasing iron availability for erythropoiesis or red blood cell production.

~~8~~7. The compound of claim 1 for the use of that claim, wherein the compound is for use in: increasing reticulocytes; increasing hematocrit; increasing hemoglobin; increasing red blood cell count; increasing mean corpuscular hemoglobin; or increasing mean corpuscular volume.

~~9.8.~~ The compound of claim 1 for the use of that claim, wherein the compound is for use in: increasing serum iron; increasing total iron binding capacity; increasing transferrin saturation; increasing soluble transferrin receptor levels; or decreasing hepcidin expression.

~~10.~~ The compound of any preceding claim for the use of that claim, wherein the compound inhibits HIF prolyl hydroxylase activity.

~~11.9.~~ The compound of any preceding claim for the use of that claim, wherein the compound is for oral administration.

Conditional amendment to claim 1 of EP 153 (in addition to the unconditional amendments):

1. A compound that inhibits hypoxia inducible factor (HIF) prolyl hydroxylase activity for use in increasing serum iron in treating iron deficiency in a subject, wherein the compound is a structural mimetic of 2-oxoglutarate.

Claims 2-7 are unchanged, Claim 8 is deleted, and Claim 9 is renumbered accordingly:

~~8.~~ The compound of claim 1 for the use of that claim, wherein the compound is for use in: increasing serum iron; increasing total iron binding capacity; increasing transferrin saturation; increasing soluble transferrin receptor levels; or decreasing hepcidin expression.

9.8. The compound of any preceding claim for the use of that claim, wherein the compound is for oral administration.